<DOC>
	<DOCNO>NCT01090310</DOCNO>
	<brief_summary>This extension study assess safety efficacy AIN457 versus placebo maintain uveitis suppression reduce systemic immunosuppression</brief_summary>
	<brief_title>Safety Efficacy AIN457 Patients With Quiescent Non-infectious Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>Patients complete entire treatment period 24 week core study Inability unwillingness undergo repeat subcutaneous injection ; inability comply study followup procedure ; medical psychiatric condition , investigator 's opinion wouldpreclude participant adhere protocol complete study per protocol . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Quiescent uveitis</keyword>
	<keyword>intermediate uveitis</keyword>
	<keyword>panuveitis</keyword>
	<keyword>posterior uveitis</keyword>
	<keyword>uveitis</keyword>
	<keyword>NVS Definition : Words phrase best describe protocol . Keywords help user find study database .</keyword>
	<keyword>Avoid acronym , abbreviation trade name .</keyword>
	<keyword>Examples : Heart failure , aliskiren , heart attack , cardiovascular disease</keyword>
	<keyword>Psoriasis , inflammatory skin disease , scaly patch</keyword>
</DOC>